LLY Lilly (Eli)

Q3 2025 10-Q

Filed: Oct 30, 2025Period ending Sep 30, 2025

Health Care

Pharmaceutical PreparationsSEC EDGAR

Lilly (Eli) (LLY) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Oct 30, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

AI Filing Analysis
Q3 2025 10-Q

Management Discussion & Analysis

• Cash and cash equivalents $9.79B as of Sept 30, 2025 vs $3.27B at Dec 31, 2024
• Total debt $42.51B as of Sept 30, 2025, up $8.86B from $33.64B at Dec 31, 2024

+3 more insights

Risk Factors

• New litigation charge from acquisition of Verve triggered asset impairment and restructuring charges of $365M for Q3 2025, up from $82M prior year
• Effective tax rate decreased to 22.8% in Q3 2025 from 38.9% in Q3 2024, impacted by lower non-deductible acquired IPR&D charges

+3 more insights

Quarterly Financial Summary
XBRL

Revenue

$17.6B

▲ +53.9% YoY▲ +13.1% QoQ

Net Income

$5.6B

▲ +475.3% YoY▼ -1.4% QoQ

Net Margin

31.7%

▲ +2323bp YoY▼ -467bp QoQ

Source: XBRL data from Lilly (Eli) Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.

Other Lilly (Eli) Quarterly Reports

Q2 2025 10-Q

Q1 2025 10-Q

Get deeper insights on Lilly (Eli)

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.